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Abstract
Background: Adenylate kinase is a key enzyme in the high-energy phosphoryl transfer reaction in living cells. An
isoform of this enzyme, adenylate kinase 4 (AK4), is localized in the mitochondrial matrix and is believed to be
involved in stress, drug resistance, malignant transformation in cancer, and ATP regulation. However, the molecular
basis for the AK4 functions remained to be determined.
Methods: HeLa cells were transiently transfected with an AK4 small interfering RNA (siRNA), an AK4 short hairpin
RNA (shRNA) plasmid, a control shRNA plasmid, an AK4 expression vector, and a control expression vector to
examine the effect of the AK4 expression on cell proliferation, sensitivity to anti-cancer drug, metabolome, gene
expression, and mitochondrial activity.
Results: AK4 knockdown cells treated with short hairpin RNA increased ATP production and showed greater
sensitivity to hypoxia and anti-cancer drug, cis-diamminedichloro-platinum (II) (CDDP). Subcutaneous grafting AK4
knockdown cells into nude mice revealed that the grafted cells exhibited both slower proliferation and reduced the
tumor sizes in response to CDDP. AK4 knockdown cell showed a increased oxygen consumption rate with FCCP
treatment, while AK4 overexpression lowered it. Metabolome analysis showed the increased levels of the
tricarboxylic acid cycle intermediates, fumarate and malate in AK4 knockdown cells, while AK4 overexpression
lowered them. Electron microscopy detected the increased mitochondrial numbers in AK4 knockdown cells.
Microarray analysis detected the increased gene expression of two key enzymes in TCA cycle, succinate
dehydrogenase A (SDHA) and oxoglutarate dehydrogenease L (OGDHL), which are components of SDH complex
and OGDH complex, supporting the metabolomic results.
Conclusions: We found that AK4 was involved in hypoxia tolerance, resistance to anti-tumor drug, and the
regulation of mitochondrial activity. These findings provide a new potential target for efficient anticancer therapies
by controlling AK4 expression.
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Background
Adenylate kinase (AK) is an enzyme that regulates
adenine nucleotide metabolism and homeostasis in a
wide range of organisms, by catalyzing the interconver-
sion reaction: ATP + AMP ⇌ 2 ADP. Nine different
kinds of human AK isozymes have been reported. AK1,
AK5, AK7, AK8, and AK9 are localized in the cytoplasm,
AK6 and AK9 in the nucleus, AK2 in the mitochondrial
intermembrane space, and AK3 and AK4 in the mito-
chondrial matrix. AK1 deficiency causes a hematological
abnormality in human [1]. AK2 is essential for growth in
D. melanogaster [2] and a genetic AK2 deficiency in
human causes reticular dysgenesis and sensorineural
deafness [3, 4], indicating the important role of AK2 in
hematopoietic differentiation as well as development of
auditory organ. Until now, we have studied the structure
and function of AK isozymes and reported that they play
important roles in cellular energy metabolism [2, 5–8].
We also reported that the therapeutic efficacy of iron
chelator, deferoxamine (DFO) for treating hepatocellular
cancer [9]. During the study, we found that AK4 gene
expression was up-regulated by DFO administration,
although the biological meaning remained unclear. The
cDNAs encoding the human and mouse AK4 gene have
been previously cloned [8, 10], and its expression pattern
has been extensively characterized in mouse tissues [5],
where AK4 was detected in the mitochondrial matrix,
but did not display any enzymatic activity. Subsequently,
other group reported that inactive AK4 interacted with
adenine nucleotide translocase (ANT) [11]. On the
contrary, another group reported that AK4 was enzy-
matically active using AMP: GTP and AMP: ATP as its
substrates [12]. Therefore, it is still controversial whether
AK4 shows classical enzymatic activity or not. The
discrepancy of enzymatic activity data seems according
to differences in the assay systems employed. Additional
functional study indicated that AK4 may be involved in
oxidative stress response by showing it as one of the
proteins up-regulated by the administration of four types
of agents that exhibit hepatic toxicity including carbon
tetrachloride [13]. We have previously reported the cell-
and tissue-specific expression profile of AK4 in mouse
tissues [5]. In addition, it was reported that nucleotide
synthesis showed in-day fluctuation, and AK4 expression
was rhythmic in murine liver [14]. Interestingly, an inde-
pendent study found that lung cancers with high AK4
expression showed increased malignancy [15]. Moreover,
it was reported that AK4 provided a valuable marker of
cellular stress in HEK293 and HepG2 cell lines [16].
Recently, Lanning et al. found that AK4 was the key
regulator of intracellular ATP levels by screening an RNA
interference (RNAi) library targeting over 1000 nuclear
DNA-encoded genes whose protein products localized to
the mitochondria [17, 18]. However, the molecular basis
for the regulation of AK4-mediated ATP levels remains
unclear, and the mechanisms how AK4 plays a role in
oxidative stress and malignant transformation and regu-
lates the mitochondria have not been elucidated. To
address these questions, we carried out both in vitro and
in vivo studies to investigate the effects of AK4 on cell
growth, mitochondrial activity, metabolome, and gene
expression.
Methods
Cell culture and reagents
HeLa cells were confirmed as the same cell line regis-
tered in the Japanese Collection of Research Bio-
resources Cell Bank (JCRB). A549 cells were purchased
form JCRB. For the hypoxia treatment, cells were cul-
tured in an incubation chamber at 37 °C, with 5 % CO2
and 1 % O2.
Animals
All experiments were carried out in accordance with the
guidelines approved by the Committee on the Ethics of
Animal Experiments at the University of Yamaguchi. All
surgery was performed under sodium pentobarbital
anesthesia, and every effort was made to minimize suf-
fering. BALB/c athymic nude mice were sacrificed using
an overdose of anesthetic.
Cell growth and ATP measurement
Cell proliferation under normoxic conditions was mea-
sured by real-time cell analysis using modified 16-well
plates (E-plate, Roche Diagnostics). Studies were con-
ducted after incubating the plated cells at 37 °C for
30 min to allow cell attachment, in accordance with the
manufacturer’s guidelines. The data were expressed as a
cell index value (CI). Changes in cell proliferation under
hypoxia were assessed using the CyQUANT® Cell Prolif-
eration Assay kit (Life Technologies) according to the
manufacturer’s instructions. The ATP concentration was
measured by the CellTiter-Glo™ Luminescent Cell Via-
bility Assay kit (Promega).
Western blot analysis
Protein lysates were obtained by homogenizing tissues
or cell pellets in sample buffer containing 62.5 mM Tris-
HCl (pH 6.8), 4 % sodium dodecyl sulfate, 200 mM
dithiothreitol, 10 % glycerol, and 0.001 % bromophenol
blue at a ratio of 1:10 (w/v), followed by boiling. West-
ern blot analysis was performed using purified polyclonal
anti-human AK4 rabbit IgG and antibodies against β-
actin (Sigma), α-tubulin (Sigma), phosphorylated 5΄
AMP-activated protein kinase (p-AMPK; Abcam),
hypoxia inducible factor 1α (HIF1α; Cell Signalling),
hexokinase 2 (HK2; Abcam), ATP5a (Abcam), and the
voltage-dependent anion channel (VDAC; Abcam),
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which were purchased from the indicated suppliers. Sub-
cellular fractionation was conducted using mitochondria
isolation kit (Thermo Fisher Scientific)sccording to the
manufacturer’s instruction.
Immunohistochemistry
HeLa cells were cultured in chamber slides for 2 days, and
then fixed in 4 % paraformaldehyde. Prior to immunohisto-
chemical staining, endogenous peroxidase in the fixed tis-
sue slices was blocked by treatment with fresh 0.3 %
hydrogen peroxidase in methanol for 30 min at 4 °C.
Blocked samples were incubated with antibodies overnight
at 4 °C. After washing 3 times in phosphate-buffered saline
(PBS), the sections were incubated with biotin-conjugated
secondary antibody in PBS for 3 h at 20 °C. After 3 add-
itional PBS washes, a peroxidase-anti-peroxidase complex
and streptavidin were added and incubation was
maintained at 20 °C. Positive reactions were developed for
5-10 min using Tris-HCl buffer containing hydrogen
peroxidase and 3,3΄-diaminobenzidine. Normal rabbit
serum (Vector Laboratories, Burlingame, CA, USA) was
used as a negative control.
Total RNA isolation
Total RNA was isolated from HeLa cells using TRIzol
Reagent (Life Technologies)), according to the manufac-
turer’s instructions. RNA samples were quantified by an
ND-1000 spectrophotometer (NanoDrop Technologies,
Wilmington, DE).
Expression and suppression of AK4
HeLa cells were transiently transfected with small interfer-
ing RNA (siRNA) or with and AK4 short hairpin RNA
(shRNA) plasmid (TRCN37554), a control shRNA plas-
mid, a green fluorescent protein (GFP)-tagged AK4 ex-
pression vector (RG220572), and a control expression
vector, purchased from Sigma-Aldrich, Tokyo, Japan or
from Origene, Rockville, USA, respectively. The siRNA
and shRNA sequences were as follows; AK4 siRNA #1,
GUCAUUGAAUUAUACAAGATT; AK4 siRNA #2, CA
UCUUUUCUAGUUGAAAUTT; AK4 shRNA, GCCA
GGCTAAGACAGTACAAA. Silencer® Select Negative
Control #1 siRNA and Control #2 siRNA were purchased
from Life Technologies. HeLa cells transfected with
shRNA were selected by puromycin. HeLa cells trans-
fected with GFP-tagged AK4 expression vector or control
vector were selected by flow cytometer and G418.
Gene expression analysis by microarrays
The cRNA was amplified, labeled, and hybridized to a
60 K Agilent 60-mer oligomicroarray, according to the
manufacturer’s instructions. All hybridized microarray
slides were scanned by an Agilent scanner. Relative
hybridization intensities and background hybridization
values were calculated using Agilent Feature Extraction
Software (9.5.1.1). G3 Human Gene Expression Micro-
array 8 × 60 K, v2, was used for analysis. The raw signal
intensities of all samples were log2-transformed and nor-
malized using the quantile algorithm of the ‘preproces-
sCore’ library package on Bioconductor software. We
selected the probes, excluding the control probes, where
the detection P-values of all samples were less than 0.01,
and used these to identify differentially expressed genes.
We then applied the Linear Models for Microarray Ana-
lysis (limma) package within the Bioconductor software.
The results derived from this study have been deposited
in the National Center for Biotechnology Information
(NCBI) Gene Expression Omnibus and are accessible
through the Gene Expression Omnibus (GEO) Series,
Accession Number GSE61843 (http://www.ncbi.nlm.
nih.gov/geo/query/acc.cgi?&acc = GSE61843).
Measurement of oxygen consumption rate (OCR)
OCR measurements were performed using a Seahorse
Biosciences XF96 Extracellular Flux Analyzer. HeLa cells
were seeded at 10,000 cells/well in XF96 microplates
(Seahorse Biosciences). After a 24-h incubation, the
growth media were exchanged for XF Assay Medium
(Seahorse Biosciences) supplemented with 25 mM glucose
(Sigma-Aldrich). OCR measurements were made over 5-
min periods following a 3-min mix period. HeLa cells
were treated by sequential addition of 1 μg/mL oligomycin
(Sigma-Aldrich), 300 nM carbonylcyanide-p-trifluoro-
methoxyphenylhydrazone (FCCP; Sigma-Aldrich), and
2 μM rotenone (MP Biomedicals). The spare respiratory
capacity and coupling efficiency were calculated according
to the Seahorse Bioscience instructions and the basal
OCR was normalized to the cell number.
Measurement of metabolites
The culture medium was aspirated from a 10-cm cell
culture dish and the cells were washed twice with 5 %
mannitol solution (10 mL, followed by 2 mL). The cells
were then treated with 800 μL methanol and left at rest
for 30 s in order to inactivate enzymes. Next, the cell ex-
tract was treated with 550 μL Milli-Q water containing
internal standards (H3304-1002, Human Metabolome
Technologies, Inc., Tsuruoka, Japan) and left at rest for
another 30 s. The extract was obtained and centrifuged
at 2300 × g and 4 °C for 5 min; 800 μL of the upper
aqueous layer was then centrifugally filtered through a
Millipore 5-kDa cutoff filter at 9100 × g and 4 °C for
120 min to remove proteins. The filtrate was centrifu-
gally concentrated and resuspended in 50 μL of Milli-Q
water for capillary electrophoresis time-of-flight mass
spectrometry (CE-TOFMS) analysis. The ratios and P-
values (t-test) were calculated by comparing cells trans-
fected with control shRNA (n = 3) with those transfected
Fujisawa et al. Journal of Experimental & Clinical Cancer Research  (2016) 35:48 Page 3 of 15
with AK4 shRNA (n = 3), or cells transfected with
control vector (n = 3) versus those overexpressing AK4
(n = 3). The data were normalized to the total cell numbers.
Electron microscopy
Cells cultured on plastic were fixed using a 2 % parafor-
maldehyde and 2 % glutaraldehyde mixture in 0.1 M
cacodylate buffer, pH 7.4, for 30 min and post-fixed in
2 % osmic acid for 1 h. The sheets were dehydrated in
graded acetone and embedded in Epon 812. Cells were
cut horizontally by an ultramicrotome (Reichert Ultra-
cut) into approximately 90-nm sections. These ultrathin
sections were stained using uranyl and lead citrate and
examined using a Hitachi H7 ultramicroscope. The
mitochondrial diameter was measured by calculating an
average of 10 electron microscopy pictures taken at ×
10,000 magnification.
Xenograft models
Ten week-old female nude mice were used for xeno-
grafting. The mice were randomly divided into four
groups. A HeLa cell/Matrigel mixture (0.2 mL) was
injected into the dorsal subcutis of the nude mice. Two
groups ofmice were treated with CDDP (5 mg/kg intra-
peritoneally, once a week). Tumor volume was calcu-
lated as follows: volume = 0.5 × length × width2.
Mitochondrial DNA (mtDNA) measurement
mtDNA content was measured by real-time polymerase
chain reaction (RT-PCR) with the Human Mitochondrial
DNA (mtDNA) Monitoring Primer Set (Takara Japan).
Briefly, we quantified mtDNA transcripts (NADH de-
hydrogenase subunit 1 (ND1) and NADH dehydrogenase
subunit 5(ND5)), and normalized these to nuclear DNA
transcripts (Solute Carrier 2B1(SLCO2B1) and Serpin
peptidase inhibitor, clade A, member 1 (SERPINA1)).
Statistics
Data correspond to the mean ± standard deviation. Un-
paired Student’s t-tests were used to compare study
groups. Analysis of variance (ANOVA) with post-hoc
analysis using Turkey’s multiple comparison test was used
for comparisons between multiple groups. P values < 0.05
were considered to be statistically significant.
Results
AK4 expression was up-regulated by hypoxia and DFO
There are several reports on the regulation of AK4
expression. Hypoxia was previously reported to up-
regulate AK4 expression in SHSY5Y and HEK293 cells,
but to down-regulate AK4 expression in HepG2 cells
[16]. Hepatotoxicans such as acetaminophen, amioda-
rone, tetracycline, and carbon tetrachloride have been
reported to induce AK4 expression [13]. We first
compared the effects of these compounds with that of
hypoxia and found that hypoxia was the most efficient
inducer of AK4 in HeLa cells (data not shown). There-
fore, in the present study we focused on the effect of
hypoxia to characterize AK4 expression in HeLa cells.
When these cells were cultured in 1 % O2, increased
AK4 protein expression was significantly observed from
12 h onwards (Fig. 1a). We then applied an iron chelator
(DFO) to the culture for 72 h, which mimics hypoxia
and is known to induce HIF1α accumulation [19]. We
observed that AK4 expression was increased in a DFO
dose-dependent manner (Fig. 1b). We also detected
DFO could increase the expression of HIF1α and HK2
in the same way. Furthermore, we analyzed the AK4 ex-
pression in A549 cells, a human alveolar adenocarcin-
oma cell line, and found that AK4 expression was
increased by hypoxia and DFO (Additional file 1: Figure
S1A and B). Our previous study indicated that both AK3
and AK4 were co-localized in the mitochondrial matrix
under normoxic conditions [20]. However, the localization
of AK4 under hypoxic conditions has not been clarified.
Therefore, we analyzed the localization of AK4 under both
normoxic and hypoxic conditions. Immunohistochemical
staining revealed that AK4 was localized within the mito-
chondria in HeLa cells cultured under 21 % O2 (Fig. 1c,
upper left panel). After culturing under 1 % O2 for 2 days,
an increased AK4 signals within mitochondria around the
nucleus were detected, but there was no evident transloca-
tion of AK4 to outside the mitochondria (Fig. 1c, lower
left panel). To confirm it, we examined the subcellular
localization of AK4 with western blotting using subcellular
fractionated samples (Fig. 1c, right panel). AK4 was specif-
ically detected in the mitochondrial fraction as shown in
the positive control, ATP5a, which is one of ATP synthase
subunits and a mitochondrial marker, but not as hexoki-
nase 2 (HK2), which associates with both mitochondrial
and cytoplasmic compartments, while HK2 expression
was enhanced by hypoxia. We then produced a stable cell
line over-expressing AK4 tagged with green fluorescent
protein (GFP) on its C terminus (AK4GFP) at a level
equivalent to that of endogenous AK4 (Fig. 1d). The GFP-
tagged AK4 localized around nuclear and merged image
with MitoTracker Red indicated that AK4 localizes in
mitochondria (Fig. 1e).
AK4 knockdown increased sensitivity to anti-cancer drug
For loss of function analysis, we used AK4 shRNA to
produce a stable knockdown of AK4 expression. West-
ern blot analysis demonstrated that transfection of AK4
shRNA effectively down-regulated AK4 protein levels
(Fig. 2a). Interestingly, the phosphorylation level of
AMPK, was significantly elevated, suggesting the increase
of AMP/ATP ratio (Fig. 2a). This finding was consistent
with A549 cell line (Additional file 1: Figure S1C) and a
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previous report [17]. However, no obvious differences in
cell proliferation were observed between the AK4
knockdown cells and control cells (Fig. 2b). To further
examine whether AK4 is necessary for hypoxic acclima-
tion, we analyzed cell growth under hypoxic conditions.
AK4 knockdown cells showed significantly reduced
proliferation under hypoxia compared to normoxia,
indicating that AK4 may play a role in hypoxic adaptation
(Fig. 2c).
As one of characteristic phenotypes in cancer cells,
hypoxia-resistant metabolism is recognized to confer in-
creased resistance to apoptosis and to chemotherapy
[21]. Therefore, we next examined the drug sensitivity of
AK4 knockdown cells. The half maximal inhibitory
concentrations (IC50) for CDDP were 1.97 ± 0.12 μM or
1.35 ± 0.22 μM in the cells expressing either control
shRNA or AK4 shRNA, respectively. For doxorubicin,
the values were 3.55 ± 0.44 μM or 2.15 ± 0.38 μM in
them (Fig. 2d). The results clearly indicated that the
level of AK4 expression was inversely correlated with
drug sensitivity. These findings were consistent with
those of A549 cell line (Additional file 1: Figure S1D and
E). To confirm the influence of AK4 on drug sensitivity
in vivo, we subcutaneously grafted AK4 knockdown cells
in matrigel into nude mice. After 40 days, we measured
the tumor volume. Tumor volume composed of HeLa
cells transfected with AK4 shRNA showed smaller
(53.2 %) compared with those transfected with control
shRNA. When CDDP was administered into mice, the
inhibition of tumor growth was greater for AK4 knock-
down cells (62.0 % of the volume of untreated AK4
knockdown cells) than for control cells (86.3 % of the
volume of untreated control shRNA cells), indicating
that down-regulation of AK4 expression increased the
sensitivity of these cells to CDDP (Fig. 2e and f). To
further analyze the drug sensitivity, we examined Western
blot analysis. The expression level of Bax was increased
and that of Bcl2 was decreased in AK4 knockout cells
(Fig. 2g).
AK4 knockdown induces mitochondrial activation
Previous studies demonstrated that siRNA-induced AK4
knockdown increased the amount of ATP per cell [17].
Consistent with this, in the present study we also found
Fig. 1 Evaluation of adenylate kinase 4 (AK4) expression and intracellular localization in HeLa cells. a Left panel: western blotting evaluation of
AK4 (25 kDa) and alpha-tubulin (55 kDa) expression at the indicated time-points under hypoxic conditions (1 % O2). Right panel: band densities
were quantified using Image Lab (BioRad) and normalized to the internal control (alpha-tubulin). *P < 0.05, **P < 0.01. b Left panel: western
blotting analysis of AK4 expression after deferoxamine (DFO) treatment. Right panel: quantified data normalized by internal control alpha-tubulin
were conducted by using Image Lab (BioRad). *P < 0.05, **P < 0.01. c Left panel: immunohistochemical evaluation of the intracellular localization
of AK4. Upper panel: normoxia; lower: hypoxia (1 % Day 2); right panel: subcellular localization of AK4. HK2 (100 kDa) was an hypoxic marker,
ATP5a (54 kDa) was a mitochondrial marker, and alpha-tubulin (55 kDa) was the loading control. d AK4 expression in a stable transformant
containing AK4 tagged with GFP on its C terminus. In addition to internal AK4 (25 kDa), overexpressed AK4:GFP (50 kDa) signaling was also
detected. VDAC or β-Actin is used for mitochondrial loading control or total protein loading control, respectively. e Intracellular localization of the
AK4GFP stable transformant. Top: GFP, center: MitoTracker Red, bottom: merged
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that down-regulation of AK4 protein expression by
siRNA was associated with increased cellular ATP
(Fig. 3a). In order to examine whether mitochondrial ac-
tivation was involved in the increase of ATP level, we
measured the OCR using a flux analyzer using stable
AK4 shRNA-expressing knockdown cells. Flux analysis
revealed that both basal and maximal respiration rates
were increased in AK4 shRNA-expressing HeLa cells
(Fig. 3b). On the other hand, we found that both basal
and maximal OCR levels were significantly decreased in
AK4-overexpressing cells (Fig. 3c). These results indi-
cated that the levels of mitochondrial oxidation are
inversely correlated with the level of AK4 expression. To
further investigate the effect of the AK4 expression level
on cellular metabolites, we performed the metabolome
analysis with CE-TOFMS. As shown in Table 1, signifi-
cant different levels of metabolites were observed in
AK4 knockdown cells compared to control cells. The
significant difference was also observed in AK4-
overexpressing cells compared to control cells as shown
in Table 2. In AK4-knockdown cells, down-regulation of
NADPH and up-regulation of NADP+ were significantly
detected, reflecting oxidative stress condition [22]. For
the mitochondrial metabolites in tricarboxylic acid
(TCA) cycle, there was a significant up-regulation of fu-
marate and malate in AK4-knockdown cells, and signifi-
cant down-regulation of succinate, fumarate, and malate
in AK4-overexpressing cells. Glutamate was also signifi-
cantly down-regulated in AK4-knockdown cells, and
Glutamate, Glutamine and glutathione were significantly
up-regulated in AK4-overexpressing cells (Fig. 3d).
Since it was speculated that these changes in the me-
tabolite levels might be due to the changes of transcrip-
tional regulation, we performed microarray analysis to
confirm the differential gene expression in AK4 shRNA-
expressing cells. As shown in Table 3, among the genes
varied in gene expression, we found several interesting
changes in gene expression that relate to the metabolic
changes. The expression of genes encoding two TCA
cycle-related enzymes, SDHA and OGDHL, were up-
Fig. 2 Decreased drug tolerance due to adenylate kinase 4 (AK4) knockdown in HeLa cells. a Left panel: western immunoblotting showing AK4
knockdown in cells expressing AK4 short hairpin (sh)RNA. AK4, 25 kDa; phosphorylated 5΄ AMP-activated protein kinase (p-AMPK), 64 kDa; β-actin,
42 kDa. Right panel: band densities were quantified using Image Lab (BioRad) and normalized to the internal control, alpha-tubulin *P < 0.05,
**P < 0.01. b proliferation curves for AK4 shRNA cells and control shRNA cells, evaluated by xCELLigence (Real Time Cell Analysis System). Cells
were evaluated after seeding at 5000 cells/well. The data are shown as mean ± standard deviation (SD) Cell Index (CI) values. c Cell numbers were
counted 3 days after seeding under normoxic and hypoxic (1 % O2) conditions *P < 0.05, **P < 0.01. d Evaluation of drug sensitivity after AK4
knockdown showing the half maximal inhibitory concentration (IC50) for cis-diamminedichloro-platinum(II) (CDDP) and doxorubicin. IC50 values
were determined by MTS assays. **P < 0.01. e Images of tumors resulting from HeLa cells grafted subcutaneously in nude mice on day 40 after
grafting. f Graph showing the volume of HeLa cell grafts in nude mice at the indicated time-points. The data are shown as mean tumor volume
(cm3) ± SD, **P < 0.01. g Western blotting analysis of HeLa cells 3 days after siRNA treatment. AK4, VDAC, Bax, or Bcl2 were detected at 25 kDa,
39 kDa, 21 kDa, or 26 kDa, respectively
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regulated. SDHA is a subunit of complex 2, and cata-
lyzes the oxidation of succinate and ubiquinone to
fumarate and ubiquinol. OGDHL is a rate-limiting com-
ponent of the multi-enzyme OGDH complex; malfunction
of this complex is associated with neurodegeneration [23].
OGDH catalyzes the conversion of 2-oxoglutarate to
succinyl-CoA and CO2 within eukaryotic mitochondria,
controlling a rate-regulating TCA cycle step. Increased ex-
pression of these enzymes would be anticipated to con-
tribute to an acceleration of the TCA cycle. We also
found altered expression of genes encoding some en-
zymes controlling the flow of TCA metabolites. GLS
is the major enzyme catalyzing the conversion of glu-
tamine to glutamate, and GLS2 increases mitochon-
drial respiration and ATP generation. We found
increases in GLS and GLS2 mRNA expression, but
there were no significant changes in the levels of
glutamate and glutamine. Expression of Transglutami-
nase (TGM2), which encodes a protein involved in
cell differentiation, proliferation, and apoptosis, was
also up-regulated. No significant changes in the ex-
pression of other AK isozymes were observed.
AK4 knockdown altered mitochondrial properties
To further examine the role of AK4 in mitochondrial
function, we investigated the mitochondrial structure in
AK4 knockdown cells using electron microscopy. The
number of mitochondria per unit surface area of cyto-
plasm was increased in AK4 shRNA-expressing cells
compared to control shRNA-expressing cells (Fig. 4a).
Then, to confirm the mitochondrial amounts, we meas-
ure the relative mtDNA level by RT-PCR. Under nor-
moxic conditions, the mtDNA level was slightly higher
in AK4 shRNA cells (1.17 ± 0.66) than in control shRNA
cells (1.00 ± 0.13), although this difference was not statis-
tically significant (P = 0.10). After culturing under 1 %
O2 for 3 days, the mtDNA count was significantly higher
in AK4 shRNA cells (1.63 ± 0.24) than in control shRNA
cells (1.00 ± 0.21; P = 0.028). When implanted in nude
mice, the mtDNA level in the tumors derived from AK4
shRNA cells was significantly higher (1.59 ± 0.13) than in
those from control shRNA cells (1.00 ± 0.12; P < 0.005)
(Fig. 4b). These results clearly demonstrated that the







Fig. 3 Oxygen consumption rate (OCR) and metabolite analysis in HeLa cells expressing adenylate kinase 4 (AK4) or control short hairpin (sh)RNA.
a Relative ATP level per cell. 10,000 cells were seeded in 96 wells, and measured 3 days after siRNA treatment. ATP level was normalized by cell
number deduced from cyquant assay. *p < 0.05. b Flux analyzer OCR measurements were performed in triplicate in cells harboring AK4 shRNA
or control shRNA before and after administration of oligomycin, carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), antimycin, and
rotenone, as indicated. *P < 0.05, **P < 0.01. c OCR of AK4-overexpressing and control cells before and after administration of oligomycin, FCCP,
antimycin, and rotenone, as indicated. d Representative metabolomics analysis of compounds involved in the tricarboxylic acid (TCA) cycle. Left:
comparison of control vector (green) and AK4 overexpression (red). Right: comparison of control shRNA (green) and AK4 shRNA (blue).
*P < 0.05, **P < 0.01
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Table 1 Metabolic analysis (AK4 shRNA vs control shRNA)
Metabolite KEGG ID Ratio P-value
N-Acetylglucosamine 6-phosphate C00357 1.95 0.006
NADP+ C00006 1.8 0.003
XA0013 No ID 1.72 0.038
UDP-glucuronic acid C00167 1.6 0.001
Inosine C00294 1.6 0.185
CoA_divalent C00010 1.55 0.005
N-Acetylcysteine C06809 1.53 0.012
Fructose 1,6-bisphosphate C00354 1.53 0.003
Cysteine C00097, C00736, C00793 1.52 0.004
Butyrylcarnitine C02862 1.51 0.011
N-Acetylglucosamine 1-phosphate C04256 1.49 0.002
1-Methyl-4-imidazoleacetic acid C05828 1.46 0.038
UDP-N-acetylglucosamine C00043 1.44 0.001
Rhein C10401 1.43 0.044
4-Guanidinobutyric acid C01035 1.41 0.005
1H-Imidazole-4-propionic acid No ID 1.41 0.031
Alanine C00041, C00133, C01401 1.38 0.001
XC0016 No ID 1.38 0.001
ADP-glucose GDP-fucose C00498, C00325 1.34 0.013
Creatine C00300 1.31 0.011
UDP-glucose UDP-galactose C00029, C00052 1.31 0.001
dTDP-glucose C00842 1.3 0.014
Adenosine 5΄-phosphosulfate C00224 1.29 0.041
Argininosuccinic acid C03406 1.26 0.008
Myo-inositol 2-phosphate No ID 1.26 0.006
Glucose 1-phosphate C00103 1.25 0.025
Pantothenic acid C00864 1.24 0.022
Isethionic acid C05123 1.23 0.129
Malic acid C00149, C00497, C00711 1.23 0.02
CMP-N-acetylneuraminate C00128 1.23 0.013
Hippuric acid C01586 1.22 0.098
XA0033 No ID 1.22 0.022
Phosphocreatine C02305 1.2 0.324
CTP C00063 1.2 0.021
N-Formylmethionine C03145 1.2 0.012
S-Adenosylmethionine C00019 1.2 0.015
GTP C00044 1.2 0.009
Cys-Gly C01419 1.2 0.34
2-Aminobutyric acid C02261, C02356 1.19 0.015
Hydroxyproline C01157 1.19 0.021
ATP C00002 1.19 0.001
Threonic acid C01620 1.18 0.03
N-Acetylaspartic acid C01042 1.17 0.007
Asparate C00049, C00402, C16433 1.16 0.009
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Discussion
Previous study demonstrated that AK4 expression was
induced in the mouse liver treated with hepatotoxicns
by proteome analysis [13], indicating that AK4 is one of
the markers for oxidative stress response. Up-regulation
of AK4 expression in cells cultured under hypoxic
conditions has also been reported [24], however, the
biological role of AK4 remains unclear.
We first verified the manner of AK4 expression in
HeLa cells. AK4 expression was up-regulated by hypoxia
(Fig. 1a), and DFO treatment which mimics hypoxia and
induces the accumulation of HIF1α by inhibiting its
hydroxylation (Fig. 1b). Immunohistochmical and sub-
cellular fractionation analyses confirmed that AK4 was
specifically induced in mitochondria (Fig. 1c). Based on
these in vitro findings using the different set, which were
Table 1 Metabolic analysis (AK4 shRNA vs control shRNA) (Continued)
Fumaric acid C00122 1.16 0.027
N-Acetylalanine No ID 1.16 0.049
UTP C00075 1.14 0.007
Threonine C00188, C00820 1.11 0.002
Homocitrulline C02427 1.07 0.041
Betaine C00719 0.91 0.034
Glutamine C00025, C00217, C00302 0.89 0.009
1-Methylnicotinamide C02918 0.89 0.049
Proline C00148, C00763, C16435 0.89 0.041
Arginine C00062, C00792 0.86 0.042
UDP C00015 0.86 0.021
dTMP C00364 0.85 0.024
NMN C00455 0.84 0.008
Taurine C00245 0.82 0.011
5-Aminovaleric acid C00431 0.81 0.001
Isovalerylcarnitine No ID 0.79 0.013
Gluconic acid C00257 0.79 0.008
N-Acetylglutamic acid C00624 0.78 0.006
AMP C00020 0.73 0.007
Ala-Ala C00993 0.71 0.36
GABA C00334 0.71 0.001
Glutathione (GSSG)_divalent C00127 0.71 0.024
dTDP C00363 0.7 0.004
XA0012 No ID 0.7 0.001
XA0027 No ID 0.7 0.02
N-Acetylputrescine C02714 0.7 0.002
Adenosine C00212 0.68 0.005
Gluconolactone C00198 0.66 0.036
dADP C00206 0.65 0.027
XC0132 No ID 0.59 0.002
GMP C00144 0.58 0.002
γ Glu-Cys C00669 0.55 0.006
2΄-Deoxyadenosine5΄-deoxyadenosine C00559, C05198 0.53 0.024
Acetylcholine C01996 0.5 0.007
3-Phosphoglyceric acid C00197 0.44 0.002
Phosphoenolpyruvic acid C00074 0.42 0.025
NADPH C00005 0.36 0.044
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Table 2 Metabolic analysis (AK4 overexpression vs control)
Metabolite KEGG ID Ratio p-value
Kynurenine C00328,C01718 6.73 0.001
Gln C00064,C00303,C00819 3.06 0.004
Glycerophosphocholine C00670 2.76 0.003
Thiamine diphosphate C00068 2.68 0.001
Glucose 1-phosphate C00103 2.63 0
Terephthalic acid C06337 2.55 0
PRPP C00119 2.45 0.016
N-Acetylglutamic acid C00624 2.42 0.004
Asn C00152,C01905,C16438 2.37 0
Pelargonic acid C01601 2.31 0.017
Glycerol C00116 2.24 0.003
Ser C00065,C00716,C00740 2.13 0
XA0033 No ID 2.04 0.024
Lauric acid C02679 2.02 0.007
Phosphocreatine C02305 2 0.01
dGTP C00286 2 0.008
Phosphorylcholine C00588 1.91 0
dCTP C00458 1.88 0.005
2-Hydroxyglutaric acid C02630,C01087,C03196 1.87 0.011
N-Acetylputrescine C02714 1.87 0
Glycerol 3-phosphate C00093 1.87 0.018
2-Aminobutyric acid C02261,C02356 1.87 0.004
Isovalerylcarnitine No ID 1.87 0.001
myo-Inositol 2-phosphate No ID 1.82 0.001
dATP C00131 1.75 0.003
Ornithine C00077,C00515,C01602 1.7 0.003
dADP C00206 1.67 0.021
3-Hydroxy-3-methylglutaric acid C03761 1.64 0.001
Putrescine C00134 1.62 0.021
Arg C00062,C00792 1.56 0.009
CTP C00063 1.55 0.034
Rhein C10401 1.54 0.023
Ala C00041,C00133,C01401 1.52 0.015
Thr C00188,C00820 1.48 0.003
ADP C00008 1.47 0.032
UDP-glucose C00029 1.46 0.017
UDP-galactose C00052
Carnosine C00386 1.46 0.029
Lys C00047,C00739,C16440 1.44 0.002
UDP-N-acetylglucosamine C00043 1.4 0.013
ADP-glucose C00498 1.4 0.003
GDP-fucose C00325
O-Acetylcarnitine C02571 1.4 0.007
GABA C00334 1.39 0.001
Table 2 Metabolic analysis (AK4 overexpression vs control)
(Continued)
Thiamine C00378 1.39 0.019
His C00135,C00768,C06419 1.38 0.003
1-Methylnicotinamide C02918 1.38 0.002
Citrulline C00327 1.36 0.012
dTDP-glucose C00842 1.35 0.008
Val C00183,C06417,C16436 1.35 0.003
Leu C00123,C01570,C16439 1.35 0.003
Gly C00037 1.33 0.005
Ile C00407,C06418,C16434 1.32 0.001
N8-Acetylspermidine C01029 1.29 0.031
Creatinine C00791 1.29 0.003
Pantothenic acid C00864 1.28 0.009
Hydroxyproline C01157 1.27 0.035
Glutathione (GSH) C00051 1.26 0.001
Phe C00079,C02057,C02265 1.26 0.007
Met C00073,C00855,C01733 1.25 0.007
Homoserinelactone No ID 1.24 0.005
Glu C00025,C00217,C00302 1.24 0.016
Pyridoxine C00314 1.24 0.025
Trp C00078,C00525,C00806 1.22 0.017
Gluconic acid C00257 1.22 0.037
N-Formylmethionine C03145 1.21 0.034
Butyrylcarnitine C02862 0.78 0.008
Succinic acid C00042 0.76 0.013
Hypotaurine C00519 0.74 0.022
Creatine C00300 0.66 0.001
Choline C00114 0.65 0.013
Ribulose 5-phosphate C00199,C01101 0.6 0.023
XA0012 No ID 0.6 0.008
Asp C00049,C00402,C16433 0.54 0.003
dTMP C00364 0.52 0.03
XC0016 No ID 0.51 0.001
Thiamine phosphate C01081 0.48 0.038
Malic acid C00149,C00497,C00711 0.47 0.006
β-Ala C00099 0.44 0.004
Fumaric acid C00122 0.44 0.006
XC0061 No ID 0.43 0.017
3'-Dephospho CoA C00882 0.42 0.034
XA0002 No ID 0.39 0.027
CMP C00055 0.38 0.019
UMP C00105 0.38 0.031
NADP+ C00006 0.36 0.001
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consistent with the previous report [15, 17], we
hypothesize that an increase in AK4 expression could
enable acclimation to hypoxia and drug resistance by
controling mitochondrial activity.
To examine the role of AK4 on cell growth in vivo, we
implanted AK4 knockdown HeLa cells into nude mice
and analyzed the tumor size. Tumor sizes formed by
AK4 knockdown cells are significantly smaller than
those by control cells. This finding might reflect the low
subcutaneous oxygen concentration, which would re-
duce the ability of AK4 knockdown cells to proliferate as
shown in Fig. 2e. Administration of CDDP inhibited the
proliferation of AK4 knockdown cells more strongly
than control cells (Fig. 2e and f), suggesting that down-
regulation of AK4 expression increased the efficacy of
anticancer drugs. Regulation of mitochondrial activity is
now one of the important points for better understand-
ing cancer biology [25, 26]. For example, the tumor cells
with reduced mitochondrial activity exhibit drug resist-
ance, where glycolysis predominates [27]. Therefore,
much attention is now focused on drugs that may in-
duce a metabolic shift from glycolysis (in the cytoplasm)
to oxidative phosphorylation (in the mitochondria) in
order to develop new cancer therapy [28]. It was shown
that increased glycolysis led to hyperpolarization of
mitochondria and inhibition of apoptosis through an
increase in the hexokinase level [29]. However, restor-
ation of mitochondrial functions could lead to apoptosis
of cancer cells concomitant with the suppression of aer-
obic glycolysis [30]. Therefore, chemical compounds
such as sodium dichloroacetate which inhibits pyruvate
dehydrogenase kinase and activates mitochondria are ap-
plicable to cancer therapy [31, 32]. In this study the ex-
pression level of Bax was increased and that of Bcl2 was
decreased in AK4 knockout cells, indicating that AK4
knockdown cell is sensitive to drug due to activation of
apoptosis. Taken together, it is suggested that the control
of AK4 expression may provide a novel anticancer target
through regulating mitochondrial activity.
For a role of AK4 expression in mitochondrial activity,
we examined the oxygen consumption rate in AK4
knockdown cells and found that it was increased
(Fig. 3b), while it was decreased in AK4 overexpression
(Fig. 3c). Moreover, metabolome analysis revealed that
TCA cycle metabolites such as fumarate and malate
were increased in AK4 knockdown cells, and conversely,
these metabolites were down-regulated by AK4 overex-
pression (Fig. 3d). Interestingly, AK4 overexpression
cells showed the increased levels of metabolites such as
Gln, Asn and GSH, suggesting the increased glutamino-
lysis and anti-oxidative activity. These findings demon-
strated the biological activity of AK4 that could support
higher proliferative activity and resistance to anti-tumor
drug in vivo.
Lanning et al. identified the changes in nucleotide
pools and central carbon metabolites in cells transfected
with AK4 siRNA compared with control siRNA, in
which the levels of ATP, fructose 1,6-bisphosphatase
(FBP), malate, and the citrate/isocitrate ratio were sig-
nificantly increased in cells transfected with AK4 siRNA,
but they did not mention about other metabolites. In the
present study, we found that the levels of ATP, FBP, and
malate were increased in AK4 knockdown cells (Fig. 3a,
Table 1). In connection with this, we found several
changes in gene expression that were correlated with the
metabolic shift. The expression of genes encoding two
TCA cycle-related enzymes, SDHA and OGDHL, were
up-regulated in AK4 knockdown cells. SDHA is a sub-
unit of complex 2, and catalyzes the oxidation of succin-
ate and ubiquinone to fumarate and ubiquinol. OGDHL
is a rate-limiting component of the multi-enzyme
OGDH complex, which catalyzes the conversion of 2-
oxoglutarate to succinyl-CoA and CO2 within eukaryotic
mitochondria. Increased expression of these enzymes
would be anticipated to contribute to an acceleration of
the TCA cycle.
From the structural viewpoint of mitochondria, elec-
tron microscopic analysis [33, 34] revealed that mito-
chondrial cross-sectional area was increased in AK4
knockdown cells. Real-time PCR analysis confirmed the
Table 3 Microarray analysis data from HeLa cell. Tricarboxylic
acid (TCA) cycle genes showing significant up-regulation are
shown in red (p < 0.05), and those showing significant down-
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increased mtDNA amounts in AK4 knockdown cells.
These morphological changes in AK4 knockdown cells
might reflect the mitochondrial metabolic activity includ-
ing TCA cycle and oxidative metabolism as shown by
metabolomic and flux analyses. These results are quite im-
portant findings because reduction of mitochondrial func-
tion and the mtDNA level is associated with tumor
progression including distant metastasis, poor survival in
early-stage laryngeal cancer, tumor invasion depth, in-
creased tolerance of hypoxia, and TMN stage [35].
Based on the findings, we propose a working model of
the role of AK4 in the regulation of mitochondrial activ-
ity (Fig. 5). Hypoxia increases the expression of AK4,
which forms the complex with HK2, VDAC, and ANT
to increase ADP recycling (Fig. 5a). The ADP that is
efficiently back to the mitochondrion is converted to
ATP by ATP synthase. ATP is consumed as a substrate
for HK2 to enhance glycolysis. A previous study demon-
strated that the interaction with the inner mitochondrial
membrane protein, ANT, is important for AK4-
mediated protection against oxidative stress [11]. How-
ever, in the absence of AK4 expression (Fig. 5b), ATP
production is increased by mitochondrial activation.
This may involve AMPK, a cellular energy sensor that
monitors the AMP level. When the cellular ATP level is
decreased, the AMP level is increased, resulting in trig-
gering AMPK phosphorylation and activation as previ-
ously demonstrated [17]. Activation of AMPK induces
mitochondrial biogenesis [36]. As shown in Fig. 2a, we
observed up-regulation of p-AMPK in AK4 knockdown
cells, suggesting an increase of cytoplasmic AMP. This
AMP increase may be caused by a reduced efficiency of
ATP transport out of the mitochondria, since it is sug-
gested that AK4 is required for forming the functional
complexes with VDAC, ANT, and CypF for efficient
ADP recycling [12]. Microarray data showed an increase
of CKMT1 expression (Table 3), which is known to form
complexes with VDAC, ANT and other substances in
the mitochondrial intermembrane space [37], suggesting
a compensational response to insufficient ADP recycling
caused by AK4 knockdown. According to the results, it
is supported that raised cellular AMP might activate
AMPK and increase p-AMPK, resulting in an increase
in ATP through promoting mitochondrial activation and
biogenesis.
AK4 knockdown produced gross changes in the levels
of fumarate and malate in the TCA cycle, possibly due
to up-regulated expression of GLS2, a mitochondrial
Fig. 4 Alteration of mitochondria by adenylate kinase 4 (AK4) knockdown. a Representative electron microscope images of cells in normoxic
condition. Left panel: HeLa cells transfected with control short hairpin (sh)RNA. Right panel: HeLa cells expressing adenylate kinase 4 (AK4) shRNA.
The arrows indicate mitochondria. Right: The graphs show the relative mitochondrial counts and cross-sectional area, as indicated. Mitochondrial
numbers were counted in ten random pictures taken at a magnification of 10,000. Mitochondrial size was determined using BZ-II analyzer
(Keyence) software. We examined 70 mitochondria in control shRNA cells and 100 mitochondria for in AK4 shRNA cells. b Relative mitochondrial
(mt)DNA copy number under the conditions indicated. mtDNA was measured by real-time PCR using the Human mtDNA Monitoring Primer Set
(Takara Japan). Briefly, we measured mtDNA (ND1 and ND5), then normalized to the nuclear DNA level (SLCO2B1 and SERPINA1). The mtDNA
content index was the ratio of mtDNA/nuclear DNA, calculated by dividing the ND1 and ND5 signals by the SLCO2B1 and SERPINA1 signals.
P < 0.05, **P < 0.01
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glutaminase, which catalyzes the hydrolysis of glutamine
to glutamate and ammonia (Table 3). It is interesting to
note that glutamine not only enters the TCA cycle via
the conversion of glutamate to α-ketoglutarate, but also
maintains the NADPH pool and may act as a precursor
for de novo pyrimidine synthesis [38]. Another possible
mechanism underlying these effects of AK4 is the com-
petitive inhibition of AK3. Both AK3 and AK4 have
highly homologous sequences and are found in the
mitochondrial matrix, and AK3 is believed to be in-
volved in supplying GDP, which is required for the con-
version of succinyl-CoA to succinate. Because AK4 is
able to bind nucleotide, substrate competition with AK3
may occur. If competitive inhibition by AK4 reduces
AK3 activity and the supply of GDP for the TCA cycle is
interrupted, AK4 would impede the reactions down-
stream from succinate and thus increase glutamate
levels. Metabolome analysis demonstrated significant
down-regulation of succinate, fumarate, and malate and
up-regulation of glutamine and glutamate, consistent
with this scenario. However, further analysis is required
to confirm the metabolic role of AK4.
Conclusion
In conclusion, our findings indicated that the AK4 expres-
sion level could modulate the anti-cancer drug sensitivity
through regulating mitochondrial activity. Control of
AK4 expression may provide a novel anticancer thera-
peutic target.
Fig. 5 A proposed role of adenylate kinase 4 (AK4) in mitochondria. a Proposed adenine nucleotide metabolism in the presence of AK4.
ADP that returns to the mitochondria is converted to ATP by ATP synthase. AK4 forms complexes with hexokinase 2 (HK2), voltage-
dependent anion channel (VDAC), and adenine nucleotide translocase (ANT) for the efficient recycling of ADP. This interaction with the
mitochondrial inner membrane protein, ANT, is important for AK4-mediated protection from oxidative stress. AK3 is thought to be
important for regeneration of GDP, which is necessary for the tricarboxylic acid (TCA) cycle. I, II, III, IV, and V indicate complexes I, II, III, IV
and V (ATP synthase), respectively. AK4 may also cause competitive inhibition of AK3, which recycles the GDP required for the TCA cycle.
b Proposed adenine nucleotide metabolism in the absence of AK4. HK2, VDAC, and ANT do not recycle ADP efficiently in the absence of
AK4. The ATP concentration decreases focally in the cytosol, leading to 5΄ AMP-activated protein kinase (AMPK) phosphorylation and
mitochondrial activation. AK4 knockdown may promote AK3 activity by canceling its inhibition to AK3. This proposed hypothesis remains
to be tested. Dotted lines indicate reduced efficiency of ADP recycling
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Additional file
Additional file 1: Supplemenal Fig. 1 Evaluation of adenylate kinase 4
(AK4) in A549 cells. (A) Western blotting evaluation of AK4 (25 kDa) and
α-tubulin (55 kDa) expression at the indicated time-points under hypoxic
conditions (1 % O2). (B) Western blotting analysis of AK4 expression after
deferoxamine (DFO) treatment. (C) Western immunoblotting showing AK4
knockdown in cells by siRNA. AK4, 25 kDa; phosphorylated 5΄ AMP-activated
protein kinase (p-AMPK), 64 kDa; β-actin, 42 kDa. (D) Cell numbers were
counted 2 days after seeding under either normoxic or hypoxic (1 % O2)
conditions. *P < 0.05, **P < 0.01. (E) Evaluation of drug sensitivity after AK4
knockdown showing the half maximal inhibitory concentration (IC50) for
cis-diamminedichloro-platinum(II) (CDDP). (Upper) IC50 curves of CDDP at
24 h, (Lower) IC50 of CDDP at 24 h. **P < 0.01 (PDF 246 kb)
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